Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C82367
http://purl.obolibrary.org/obo/NCIT_C82367
Preferred Name

Enoticumab
Definitions
A human monoclonal antibody directed against Delta-like ligand-4 (DLL4) with potential antineoplastic activity. Enoticumab specifically binds to human DLL4, preventing its binding to Notch receptors and inhibiting Notch signaling, which may result in defective tumor vascularization and, so, the inhibition of tumor cell growth. DLL4 is the only Notch ligand selectively expressed on endothelial cells; DLL4/Notch signaling is required for the development of functional tumor blood vessels.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A human monoclonal antibody directed against Delta-like ligand-4 (DLL4) with potential antineoplastic activity. Enoticumab specifically binds to human DLL4, preventing its binding to Notch receptors and inhibiting Notch signaling, which may result in defective tumor vascularization and, so, the inhibition of tumor cell growth. DLL4 is the only Notch ligand selectively expressed on endothelial cells; DLL4/Notch signaling is required for the development of functional tumor blood vessels.
prefLabel
Enoticumab
label
Enoticumab
PDQ_Closed_Trial_Search_ID
640973
code
C82367
Has_Target
prefixIRI
NCIT:C82367
in_subset
Display_Name
Enoticumab
Preferred_Name
Enoticumab
FDA_UNII_Code
B59DCD0F7D
Contributing_Source
CTRP
FDA
Maps_To
Enoticumab
CAS_Registry
1192578-27-0
NCI_Drug_Dictionary_ID
640973
Legacy Concept Name
Anti-Dll4_Monoclonal_Antibody_REGN421
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
640973
Semantic_Type
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
UMLS_CUI
C2830058
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display